Introduction
Fibrosis is defined as an imbalance between ECM production and degradation and is a disorder characterized by excessive deposition of matrix proteins and architectural distortion of connective tissues as a result of physical trauma, autoimmunity, infection, foreign implants, or exposure to toxic substances. The synthesis and turnover of ECM are essential for normal tissue organization and function both during the development of adaptive homeostasis and in the tissue remodeling that occurs after injury. Chronic trauma and long-term stimuli are reported to cause dysregulation of ECM synthesis, which leads to pathologic fibrillar collagen and noncollagen protein production and consequently results in tissue fibrosis (Fig. 1) . If highly progressive, the process of fibrosis can lead to organ dysfunction, which can occur in diverse organs, such as the liver, kidney, lung, heart, skin, eye, and oral mucosa [1, 2] (Fig. 2) .
Although substantial progress has been made in understanding the pathogenesis of fibrotic disorders, there is still no cure. Early identification and subsequent elimination or control of the trigger of particular fibrotic diseases are still the best approaches for successful treatment. Successful removal of the causative pathogen, for example, results in regression of fibrosis in HBVand HCV-infected individuals, as well as in schistosomiasis patients [3, 4] . Surgery is still the standard treatment for Dupuytren's contracture, the capsular contracture formed around implants, and for hypertrophic scarring. The fibrotic tissue is excised, but relapses are frequent. Injection of collagenase from Clostridium histolyticum, as a nonsurgical and thereby less invasive option, has been reported recently as a treatment for Dupuytren's disease. Collagenase significantly reduced contractures and improved the range of motion in affected joints. In addition to mild local side effects (e.g., bruising, pruritus, swelling), tendon ruptures have been described after collagenase treatment, owing to uncontrolled digestion of neighboring collagenous structures [5] . Development of anti-TGF-b1 antibody therapy is still under way; some humanized mAbs specific to individual ligands, such as lerdelimumab and metelimumab, were eventually abandoned because they failed to show efficacy in fibrotic models of corneal scarring and systemic sclerosis, respectively. Fresolimumab has progressed further in clinical practice for both neoplastic and non-neoplastic applications [6] . Imatinib, a small-molecule tyrosine kinase inhibitor that targets both the TGF-b and platelet-derived growth factor signaling pathways, has been indicated to inhibit the development of fibrosis and to induce regression of pre-existing fibrosis in experimental animal fibrotic models [7] . Based on the poor tolerance and minimal potency observed for this drug in a randomized placebo-controlled, double-blind trial in patients with IPF [8, 9] , it is also not an ideal therapy. Therefore, safe and effective anti-fibrotic drugs that specifically target fibrosis are badly needed. Halofuginone, an analog of febrifugine, inhibits tissue fibrosis and can actually be targeted to the desired fibrotic location without affecting collagen synthesis elsewhere. In recent years, halofuginone has attracted much attention because of its wide range of beneficial biologic activities, such as in malaria, diarrhea, and cancer and especially in fibrosis-related diseases. Many studies involving anti-fibrotic research in various organs showed that the promising drug halofuginone had prominent effects in the treatment of fibrosis.
The aim of this review is to highlight future avenues for possible research efforts particularly concerning the mechanism of this type of bioactive molecule in combating fibrosis.
FIBROSIS
Fibrosis (from the Latin fiber = filament, thread) is defined as an excessive deposition of collagenous and noncollagenous ECM components in tissues as a consequence of injury or long-term inflammation, and collagen I is the major constituent. Although the synthesis and systemic accumulation of collagen and noncollagen matrix proteins are essential for normal tissue development and wound repair, excessive matrix accumulation leads to pathologic fibrosis. In addition to ECM synthesis and deposition, fibrosis involves inadequate degradation, removal, and clearance of the ECM. In the extracellular space, matrix degradation occurs predominantly as a consequence of the coregulation of the MMPs and the TIMPs, which closely regulate MMP activity [10, 11] . Recent studies elucidated that ECM can be synthesized by diverse cells. In some cases, such as in skin, pulmonary, and kidney fibrosis, fibroblasts are thought to play a pivotal role in collagen synthesis [12, 13] . In the liver and pancreas, other resident cells-the stellate cells-were found to be the cellular source of collagen and other ECM molecules [14, 15] . Regardless of their origin and responses to the fibrogenic stimulus, the cells are quiescent with low proliferation rates and differentiate into myofibroblast-like cells with a high proliferative capacity and an ability to synthesize large numbers of ECM molecules, especially collagen I [16, 17] . The pathogenesis of fibrotic disorders is similar in diverse tissues, and the cellular mechanism of fibrosis is shared among various insults and in many aspects, mirrors the scarring and wound-healing processes. The TGF-b cascade, for example, which plays a major role in fibrosis, involves the binding of a ligand to a serine-threonine kinase type II receptor that recruits and phosphorylates a type I receptor. This type I receptor subsequently phosphorylates SMADs, which function as downstream effectors, typically by modulating target gene expression. The TGF-b superfamily, which constitutes multiple signaling cascades, is too complex to review in detail here; however, its diversity highlights the complexity of fibrosis regulation. Recently, another cell mechanism involved in fibrosis has been suggested and involves Th17 cells, a distinct subset of CD4 + T cells that produce IL-17A as a proinflammatory cytokine, which is emerging as an important driver of fibrosis. IL-17A expression has been implicated in the pathogenesis of pulmonary fibrosis [18] , chronic allograft rejection [19] , fibrosis in orthotopic lung transplantation [20] , myocardial fibrosis [21] , and hepatitis-induced hepatic fibrosis [22] . In many cases, IL-17A expression is associated with persistent neutrophilia [23] , and exaggerated neutrophil recruitment contributes to the development of tissue damage and fibrosis by inducing apoptosis in vascular endothelial cells [24] . In addition to its role in promoting neutrophilic inflammation, IL-17A has been shown to induce expression of MMP-1 directly in primary human cardiac fibroblasts [25] , suggesting that IL-17A promotes fibrosis by both exacerbating the upstream inflammatory Figure 1 . Balance between the degradation and synthesis of ECM molecules in healthy and fibrotic body: a healthy body maintains homeostasis; that's to say, the production, deposition, and degradation of ECM are in balance. After injury or chronic inflammation, a wound-healing response tries to restore tissue structure and function with newly produced ECM. If the response is dysregulated, or the damage is too severe, then the tissue repair process may advance into fibrosis.
response and regulating the downstream activation of fibroblasts. Moreover, IL-17A was reported to be linked to TGF-b1 [18] . Together, these data identify the IL-17A-TGF-b1 cytokine axis as an important pathway in inflammation-driven fibrosis. Apart from being defined as an excessive accumulation of the ECM (such as collagen and fibronectin), in and around inflamed or damaged tissue, fibrosis is also a major pathologic feature of many chronic autoimmune diseases, including scleroderma, rheumatoid arthritis, Crohn's disease, ulcerative colitis, myelofibrosis, and systemic lupus erythematosus. Many distinct immunologic and molecular mechanisms contribute to the progression of fibrotic disease. Dysregulated innate and adaptive immune responses are major contributors to fibrosis. Notably, fibrosis is estimated to contribute to ;45% of deaths in industrialized countries [26, 27] . Thus, the demand for safe and effective drugs is on the rise. Although fibrogenesis is becoming increasingly recognized as a major cause of morbidity and mortality in most chronic inflammatory diseases, there are few treatment strategies available that specifically target some aspect of fibrosis pathogenesis. One of the major obstacles slowing the development of anti-fibrotic drugs is the lack of disease-specific biomarkers that can be used to identify patients who might benefit from a specific therapy. Thus, a more integrated anti-fibrotic strategy that simultaneously targets important inflammatory mediators, profibrotic cytokines, and intrinsic cell and/or tissue changes will probably emerge as the most successful way to treat this highly complex and difficult-tomanage pathology.
HALOFUGINONE
Halofuginone (Fig. 3) , first described in 1975, is a low MW quinazolinone alkaloid (495 Da) isolated from the plant Dichroa febrifuga and is a U.S. Food and Drug Administration-approved feed additive for prevention of coccidiosis in broiler chickens and growing turkeys [28] . In the early 1990s, it was observed that even low concentrations of halofuginone inhibited collagen I synthesis [29, 30] . The efficacy of halofuginone in reducing collagen I was demonstrated in a broad range of cell types of chicken, mouse, rat, and human origin, both in vivo and in vitro [30, 31] . In addition to inhibition of collagen I production, halofuginone significantly decreased tissue fibrosis by suppressing the expression of MMP-2 [32] and TGF-b1 [31] . Moreover, it was also found to reduce fibrotic processes and adhesion formation induced by variable agents in human tissues [33] [34] [35] [36] . The first published study of halofuginone used in a human involved its topical application on the neck skin of a patient with cutaneous cGvHD, a condition marked by significant skin fibrosis and contractures; after 6 mo of halofuginone application, there was a marked reduction in collagen synthesis in the skin of this patient [37] . In addition, a pharmacokinetic study in rats set the stage for the systemic use of this drug in humans, showing that after i.v. administration in rats, halofuginone rapidly distributed to all tissues except the brain. Most importantly, regarding its potential use in Duchenne muscular dystrophy patients, this study showed that halofuginone persisted in lung and skeletal muscle longer than in plasma. No metabolites of the drug were measured in plasma or tissues, and it was only toxic at extremely high doses [38] . Furthermore, it has been proven that halofuginone prevented ECM collection; suppressed fibroblast functions, angiogenesis, and neovascularization; and decreased postoperative adhesions when used systemically and topically [31, 39] . In recent years, research has indicated that halofuginone, as a specific inhibitor of collagen I, has not only started to be applied clinically, as seen in the treatment of scleroderma, but can also be used as a new inhibitor of tumor growth and metastasis, including for tumors of the bladder, prostate, breast, skin, and lung. These research findings have led to a Phase I trial, the prospect of which is promising [30, 40, 41] .
THE MODE OF ACTION OF HALOFUGINONE
Inhibition of Smad3 phosphorylation downstream of the TGF-b signaling pathway TGF-b, the major cytokine driving tissue fibrosis, has been shown to regulate multiple fundamental cellular processes, including cell growth, migration, adhesion, ECM deposition, and apoptosis [42] [43] [44] , and signals via Smad3 [45] . The TGF-b signal is transduced through TGF-bR-I (also known as activin receptorlike kinase 5) and TGF-bR-II (a serine/threonine protein kinase) [46, 47] . The binding of TGF-b induces TGF-bR to phosphorylate the GS domain of TGF-bR-I. Essential downstream effectors, including Smad proteins and MAPK, are then activated by the phosphorylated receptor complex [48] . In Smad signaling, the phosphorylated receptor complex recruits R-Smads, including Smad2 and Smad3, and activates them by phosphorylation. The activated R-Smads form heterodimers and further complex with Smad4 and then translocate into the nucleus to regulate transcription. In addition, other non-Smad signaling pathways, including Rho/Rho-associated protein kinase, MAPKs, phosphatase 2A, STAT/NF-kB, and PI3K/Akt, can also engage in crosstalk with Smad signaling and therefore, modulate fibrotic processes [49] (Fig. 4) .
The anti-fibrotic agent, halofuginone, interferes with TGF-b signaling by inhibiting Smad3 activation through at least 2 distinct mechanisms: 1 is the down-regulation of the levels of TGF-b RII, and the other is inhibition of the phosphorylation and subsequent transcriptional activation of Smad3. This inhibitory property is specific to Smad3, as there was no inhibitory effect observed on the activation of Smad2 [31] . Research on the TGF-b signaling pathways demonstrated that halofuginone inhibited DNA binding and nuclear localization of Smad3 after TGF-b stimulation and that this effect is a result of the inhibition of Smad3 phosphorylation, which was due, at least in part, to halofuginone-dependent activation of Akt MAPK/ERK and p38 MAPK phosphorylation. Halofuginone promotes the phosphorylation of Akt and MAPK family members, resulting in decreased Smad3 phosphorylation in a dose-dependent manner without affecting Smad3 levels [50] . Additionally, both the MAPK/ERK and PI3K/Akt pathways are implicated in the myogenic lineage; the MAPK/ERK pathway has been reported to be involved mainly in the early stages of myoblast proliferation [51, 52] , whereas the PI3K/Akt pathway has been shown to be crucial for later stages of myoblast terminal differentiation and cell survival [53] [54] [55] . The role of MAPK/ERK in mediating the TGF-b signaling pathway remains unclear. Some reports showed that TGF-b induced MAPK/ERK phosphorylation, which in turn, enhanced TGF-b responses [56, 57] , whereas others reported that the MAPK/ERK pathway was activated by ligands other than TGF-b or by overexpression of activated upstream molecules of ERK, which disrupted Smad3 activation [58, 59] . Apart from the disruption of Smad3 signaling, halofuginone has also been found to activate the PI3K/Akt and ERK pathways in muscle cells [50] , c-Jun signaling in mouse embryonic fibroblasts [60] , and NF-kB and p38 MAPK in hepatic stellate cells [61] and to inhibit NF-kB and p38 MAPK in activated T cells [62] (Fig. 5) . As indicated by the above reports, the effects of halofuginone may be highly dependent on the cell type and/or the cellular signaling context. It should be noted that other mechanisms cannot be ruled out, such as the involvement of Smad7, a molecule upregulated by halofuginone in a variety of cell types, including fibroblasts, hepatic, and pancreatic stellate cells; tumor cells; and myoblasts [50, [63] [64] [65] . Halofuginone is the first molecule shown to inhibit directly TGF-b-induced Smad signaling, and in this respect, it may become crucial not only as a therapeutic agent for fibrosis but also as a basic research tool in TGF-b biology [31] .
REDUCTION OF COLLAGEN AMOUNTS
Collagens are a superfamily of closely related proteins that play a dominant role in maintaining the structural integrity of various tissues. Nineteen collagen types, containing altogether .30 distinct polypeptide chains, have now been identified, and their genes have been found to be dispersed among at least 12 chromosomes [66, 67] . Collagens are involved in a variety of developing cell programs, such as cell adhesion, cell movement, and physiologic processes, including homeostasis, tissue remodeling, and wound healing [68, 69] . Of the growing number of distinct collagen types, fibrosis is especially associated with an increase in type I production, which in some cases, is accompanied by up-regulation of collagen III.
The mode of action of halofuginone in decreasing collagen amounts is mainly a result of the following properties of the drug: 1) inhibition of proliferation of fibroblasts, 2) reduction of the capacity of fibroblasts, and 3) a selective inhibitory effect on type I collagen.
In the generation of fibrosis, one of the most important cell types for collagen deposition in the interstitium of organs is the fibroblast and its subtypes, which include myofibroblasts and other, as yet poorly characterized, cells [70, 71] . It has been proven that pretreatment with halofuginone can block TGFb-induced up-regulation of fibroblasts, which are the main source of collagen production [31] . Moreover, halofuginone has been reported to promote MAPK/ERK phosphorylation in mdx myoblasts [50] . The MAPK/ERK pathway has been indicated to mediate myoblast proliferation [51, [53] [54] [55] ]. An interesting finding was that halofuginone inhibited the proliferation of fibroblasts, which are collagen-producing cells, but not keratinocytes, which do not produce collagen. Although correlative, these results suggested that the effect of halofuginone on cell proliferation was secondary to the inhibition of collagen synthesis [72] . For example, halofuginone inhibited C6 glioma cell proliferation only after implantation in nude mice at the time when the cells expressed the collagen a1(I) gene but not in culture when no collagen synthesis occurred [73] , and in the cirrhotic liver, halofuginone suppressed proliferation of stellate cells, which are the major collagen-producing cells [74] . Above all, halofuginone blocks collagen synthesis, via inhibition of the proliferation of fibroblasts, by prohibition of the TGF-b signaling pathway and acceleration of MAPK/ERK phosphorylation.
Apart from the inhibition of proliferation of fibroblasts, the suppression of the capacity of fibroblasts is also of great importance for treating fibrosis. In fibrosis, fibroblasts under mechanical load stress develop prominent actin stress fibers and organize a fibronectin matrix [75, 76] . Treatment of mechanically loaded cells with TGF-b results in their differentiation into myofibroblasts [77] , the a-SMA-containing cells that are involved in wound contraction in vivo [78] . Halofuginone has been proven to abrogate the secretion of TGF-b, and as a result, the Figure 5 . Inhibition of the Smad3 pathway by halofuginone in the fibroblast: TGF-b is the major activator of the Smad3 pathway. The phosphorylated Smad3 (P-Smad3) translocates to the nucleus and regulates target gene transcription. Halofuginone, which binds to tyrosine kinase receptors (TRK) and/or directly infiltrates into the cell, activates the PI3K and MAPK family signaling pathways. The phosphorylated Akt and ERK, but not the phosphorylated JUN and p38, associate with the unphosphorylated Smad3, thereby prohibiting its phosphorylation. With the activation of the PI3K and MAPK family pathway and the inhibition of the Smad3 pathway, halofuginone reduces collagen production and then abrogates inhibition with the consequence of improving tissue histopathology and function. differentiation of fibroblasts to myofibroblasts is inhibited. In animal models of fibrosis, in which excess collagen is the hallmark of the disease, halofuginone prevented differentiation of the fibroblasts to myofibroblasts and thereby, inhibited collagen synthesis [79] . These models included abdominal, uterine horn, and urethral adhesions [39, 80, 81] and chemically induced fibrosis of the liver and pancreas [64, 82] , pulmonary fibrosis [83] , muscle fibrosis in various dystrophies [84] , and skin fibrosis in cGvHD-afflicted mice and the Tsk + mouse model of scleroderma [72, 85] . By contrast, unlike mechanically loaded cells, fibroblasts in collagen matrices in the absence of a mechanical load become quiescent within 24 h, at least in part, because of down-regulation of the ERK pathway [86] . In fibrosis, fibroblasts become active upon mechanical load stress and thereby, synthesize collagen. In a previous study, halofuginone, at concentrations that did not alter fibroblast proliferation, was shown to reduce the capacity of fibroblasts to contract unloaded collagen lattices by activating the ERK signaling pathway [87] . The ERK1, -2 (a member of the MAPK superfamily) and p38 kinases are activated in fibroblasts during collagen matrix contraction under isometric tension [88] , and they cooperate in contraction-stimulated activation of the immediate early gene c-fos. These kinases are modulated when fibroblasts contract stressed collagen matrices, although they are not required for lattice contraction per se [89] . Kamakura et al. [90] demonstrated that the ERK1, -2 inhibitors PD98059 and U0126 inhibited MEK5, in addition to ERK1, -2. MEK5 is a member of the MAPK kinase family and is the kinase that directly and specifically phosphorylates ERK5, suggesting that MEK5 may be involved in the inhibitory effect of halofuginone on collagen lattice contraction by fibroblasts. Therefore, inhibition of collagen synthesis, by reducing the capacity of fibroblasts, absolutely has proven to be a new field to be explored. Collagen I, which is the most abundant type of collagen, plays a significant role in fibrosis. Halofuginone has a selective inhibitory effect on collagen I. The inhibitory effect is generally the result of 2 mechanisms: 1) the degradation of collagen and 2) the inhibition of collagen synthesis. Halofuginone promotes the resolution of established fibrosis by dissolving collagen in animal models and in humans, which sets it well apart from all other anti-fibrotic agents. In the Tsk mouse, halofuginone treatment caused a decrease in the pre-existing fibrotic condition, as indicated by changes in collagen gene expression, collagen content, and skin morphology [72, 85] . In rats with established liver fibrosis, the administration of halofuginone resulted in the complete resolution of fibrosis. The levels of collagen, collagen a1(I) gene expression, TIMP II, and a-SMA-positive cells, all of which are characteristic of activated myofibroblasts, were reduced almost to the control levels [72] . Halofuginone applied locally in a cGvHD patient caused a marked reduction in the collagen content of the skin [37, 91] . This was probably a result of up-regulation of the collagen degradation pathway by inhibition of TIMP II and activation of MMP activities. Halofuginone has also been shown to have a pronounced stimulatory effect on MMP-3 and -13 and to have an inhibitory effect on MMP-2, thereby promoting collagenolytic activity [61] . Moreover, halofuginone also appeared to inhibit collagen I synthesis by affecting the transcript level of the collagen a 2(I) (COL1A2) gene and down-regulating collagen a 2(I) mRNA production, which was a result of a reduction in the promoter activity of the collagen I genes [31] . Halofuginone has been proven to reduce collagen a 1 (I) gene expression, whereas no such effect has, thus far, been observed for types 2, 3, or 10 [82] . However, the reduction in collagen synthesis by halofuginone appears not to be a direct effect of halofuginone on the collagen a1(I) promoter but rather, is dependent on new protein synthesis. Simultaneous treatment of fibroblasts with protein synthesis inhibitors, such as cycloheximide or actinomycin D, blocks the suppressive effect of halofuginone on collagen a1(I) mRNA gene expression [92] . Apart from these mechanisms, halofuginone can also inhibit collagen synthesis through affecting TGF-b pathways. TGF-b stimulation has been reported to up-regulate the production of collagen I, III, and VII and fibronectin and to regulate the expression of several MMPs, including MMP-1, -2, -3, and -13 [93] . Halofuginone had no effect on expression of either TGF-bR-I or -II, demonstrating that halofuginone blocks TGF-b-induced up-regulation of collagen synthesis by some mechanism other than receptor downregulation [31] . Some existing reports demonstrated that the inhibition of TGF-b-mediated collagen synthesis was a result of the decrease of the activation of Smad3 through increased expression of Smad7, an inhibitor of Smad2/3 activation, and as a result of a c-jun-dependent mechanism [31, 33, 60] . Thus, the specific mechanism by which halofuginone inhibits collagen synthesis remains to be determined.
Currently, halofuginone is the only known type-specific inhibitor of collagen. Halofuginone was found to affect collagen a1(I) gene expression in soft tissues but not in bone. The first intron of the collagen a1(I) gene is a putative site for halofuginone-dependent transcriptional regulation, as unlike fibroblasts, osteoblast and odontoblasts do not appear to use this site for transcriptional regulation [94] . The halofuginonedependent inhibition of collage content is reversible, and the achievement of sustained reduction necessitates continuous halofuginone treatment [95] .
DECREASES IN ECM PROTEIN
ECM is a multimolecular complex structure comprising fibers of collagen, elastic fibers, structural glycoproteins (including fibronectin and laminin), and mucopolysaccharides. The reduction of collagen, the main component of ECM, has been described in detail earlier in this review, and here, we mainly focus on the inhibition of other proteins in the ECM. ECM components function in a 3-dimensional network mode and physiologically keep balance among the processes of synthesis, deposition, and degradation. Excessive ECM degradation leads to fibrolysis and tissue destruction, whereas increased ECM synthesis results in fibrogenesis and scarring. Fibrosis is the result of a disruption of the balance of the ECM metabolism, increasing synthesis and deposition on one hand and decreasing degradation on the other hand.
Halofuginone reduces ECM synthesis and deposition by inhibiting the TGF-b signaling pathway in fibroblasts [96, 97] , thereby prohibiting the differentiation of fibroblasts into myofibroblasts [79] . Halofuginone blocks the TGF-b signaling pathway to phosphorylate downstream Smad3 in various cell types [31, 33, 79, 92, 98] . However, it has also been shown that TGF-b transactivated the fibronectin gene through a JNK-specific, Smad-independent mechanism [99] . Therefore, halofuginone probably abrogates fibronectin production by suppressing the TGF-b signaling pathway. Fibroblasts, the most common cell type of the connective tissues and the principal source of the extensive ECM, are mainly responsible for the production and turnover of adhesive proteins (e.g., laminin and fibronectin), structural proteins (e.g., fibrous collagen and elastin), and ground substance (e.g., glycosaminoglycans) of the ECM. In pathologic fibrosis, the fibroblasts change their morphology to become myofibroblasts, which possess migratory capabilities and are the primary source for ECM secretion [36, [100] [101] [102] [103] [104] . In principle, there are several strategies that could be applied to target myofibroblasts. These include inhibition of fibroblast recruitment to the site of interest, reduction of the occurrence of the fibroblast-to-myofibroblast transition and epithelial transdifferentiation, interference with the crosstalk between the myofibroblasts and the neighboring epithelial cells (cancer cells or others), activation of myofibroblast apoptosis, and suppression of the ability of the myofibroblasts to proliferate, migrate, and synthesize large amounts of ECM constituents [105] . Apart from the fact that myofibroblasts are responsible for wound healing and scar formation [106, 107] , the myofibroblast transition depends on the synthesis and secretion of specific ECM components, such as a fibronectin splice variant containing the ED-A fibronectin [108] . The conformation of fibronectin is changed by the insertion of the ED-A module, and cell adhesion to fibronectin thus increases [109] . In TGF-b-mediated myofibroblast transdifferentiation, it is essential that the ED-A segment of fibronectin interacts with the cell surface [107, 108] . Furthermore, the polymerization of fibronectin into the ECM is required for the accumulation of other types of ECM components, such as collagen I [110] . These findings indicate that deposition and accumulation of collagens, which are characteristic of the fibrotic ECM, can be influenced by changes in the deposition of noncollagen molecules within the ECM. Additionally, other ECM changes in collagen-binding molecules regulate the myofibroblast phenotype. For example, fibroblasts isolated from human oral mucosa are resistant to TGF-b-driven myofibroblast conversion [111] , which has been associated with scarfree healing of the oral mucosa. Retention of myofibroblasts in fibrosis has been described as the result of imbalanced cytokine signals, as the conversion of fibroblasts to myofibroblasts is mediated by elevated levels of TGF-b, and myofibroblasts contribute to their own continued survival by secreting activated TGF-b. A study of lung fibrosis showed that IL-1b induced apoptosis in myofibroblasts through iNOS at the end of the normal healing process, but this pathway was blocked by TGF-b, indicating that any condition that causes elevated levels of TGF-b could inhibit the death of myofibroblasts and result in fibrosis [112] . Furthermore, sources of TGF-b include eosinophils [113] , which can be retained by a hyaluronan-rich ECM [114] . TGF-b causes increased retention of hyaluronan in the ECM [111, 115] , and myofibroblasts secrete TGF-b, closing the loop of an autostimulatory cycle. Hence, myofibroblasts are responsible for the deposition of a dense, fibrotic collagen matrix [116] , and inhibition of these cells may possibly decrease the degree of fibrosis.
Halofuginone increases the degradation of ECM by way of enhancing MMP activity and down-regulating TIMPs. The MMPs are a family of highly homologous, metal-dependent endopeptidases that can cleave the majority of the constituents of the ECM, such as collagen, fibronectin, laminin, and elastin [103] , so they are considered as physiologic mediators of ECM turnover [117] . MMPs belong to a group of proteolytic enzymes that are able to degrade the ECM, whereas their endogenous TIMPs bind to the active site of the MMPs in a stoichiometric 1:1 molar ratio, thereby blocking access to ECM substrates and inhibiting ECM degradation [118] . Most of the MMPs (such as MMP-2, -9, and -13) are anti-fibrotic, as they suppress the expression of collagen I and III [119] , whereas MMP-19 is able to cleave other components of the ECM, such as the laminin 5g2 chain, nidogen-1, tenascin C, and aggrecan, among others [120] [121] [122] [123] . The role of MMP-19 appears to be prominent in cell types or in compartments where ECM substrates, as well as MMP-19, are simultaneously available, as was documented in a study showing that MMP-19 deficiency causes an accumulation of tenascin-C in the bronchial walls of mice suffering from asthma [124] . Notably, it has recently been reported that MMP-19 may play a protective role during the development of lung fibrosis [125] . The proteinase-anti-proteinase paradigm states that net MMP proteolysis in a tissue is the sum of the total active MMPs minus the inhibition by TIMPs [119] . Therefore, tight regulation of MMP and TIMP activities is essential to promote excessive matrix degradation. The ability of halofuginone to elicit the resolution of pre-existing fibrosis probably arises from the enhanced MMP activity [32] and down-regulation of TIMPs mediated by the drug [65, 74] . Although there are many mechanisms for generating fibrosis that are common among different organs, notably, including the stable activation of myofibroblasts from resident interstitial cells and common immune features, it is important to note that the roles for specific MMPs are not necessarily the same among different organ systems [119] . MMP-8, for instance, which demonstrated an anti-fibrotic effect in a bile duct ligation-induced liver model, promoted fibrosis in the lung [119] .
SELECTIVE PREVENTION OF THE DEVELOPMENT OF TH17 CELLS
Th17 cells, a distinct subset of CD4 + T cells with IL-17 as their major cytokine, regulate the pathogenesis of inflammation, and dysregulated Th17 cells contribute to inflammatory and autoimmune diseases [126] . Th17 cells secrete not only IL-17A but also IL-17F, IL-21, IL-22, and IL-23; these cytokines most likely cooperate to induce multiple inflammatory and hematopoietic effects on epithelial, endothelial, and fibroblastic cells [127] . Halofuginone has recently been reported to inhibit selectively Th17 cell differentiation generally by activating the AAR, elevating the activation of ERK, reducing STAT-3 levels, and inhibiting the NF-kB signaling pathway (Fig. 6) .
Halofuginone selectively inhibits the differentiation of Th17 cells and mediates autoimmune inflammation via the cytoprotective AAR pathway. It does so by binding to EPRS, inhibiting ProRS activity, and thereby causing intracellular accumulation of uncharged tRNA and mimicking reduced cellular proline availability, while simultaneously occupying 2 different substrate-binding sites on ProRS [128] without affecting maturation of other T cell lineages [96] . A previous study proved that halofuginone protected mice from Th17-associated EAE by inducing the AAR pathway [129] . The mechanism likely involved activation of the integrated stress response, which is a coping mechanism that supports cells experiencing metabolic, oxidative, and hypoxic stresses and regulates amino acid metabolism and resistance to oxidative stress [97] . Another study indicated that IDO, an IFNg-induced enzyme expressed by dendritic cells that metabolizes tryptophan, causes local amino acid depletion and inhibits the proliferation of bystander Th17 cells via the AAR [130] . Therefore, it is clear that the AAR pathway plays a significant role in the differentiation of Th17 cells. Additionally, it should be noted that TGF-b is required for promoting differentiation of the inflammatory Th17 cell subset, which suggests an existing link between the TGF-b and AAR pathways. In mice, Th17 differentiation was initiated by TGF-b and IL-6, expanded by IL-21, and stabled by IL-23 [131] . In humans, the combination of TGF-b and IL-21 was sufficient to induce differentiation of naïve T cells. There are at least 2 functional subclasses of Th17 cells, including cells bearing IL-17 receptor A and those bearing IL-17 receptor C, distinguished by their development in the presence or absence of TGF-b [132] . Therefore, the activation of the AAR pathway by halofuginone can also be done by inhibition of TGF-b. Apart from the activation of AAR pathways, the effects of halofuginone on Th17 differentiation also included increased signaling via ERK. Some existing studies showed that ERK signaling, regulated by TGF-b1, was found to potentiate the production of IL-2 and activate STAT5 and led to induction of reciprocal FoxP3 (T reg -specific transcription factor), which occurs only under Th17-polarizing conditions. These findings raised the possibility that the activation of ERK upon Th17 differentiation is involved in mediating reciprocal changes in IL-17 and FoxP3 expression upon halofuginone treatment [133] [134] [135] [136] .
Halofuginone reduces the expression of STAT3, thus downregulating Th17 cell differentiation. STAT3, a master regulator of this pathogenic T cell subtype, favors Th17 cell differentiation. A hyperactive form of STAT3 promoted the development of Th17 cells, whereas this differentiation process was greatly impaired in STAT3-deficient T cells, and overexpression of a constitutively active form of STAT3 increased IL-17 production [137, 138] . Additionally, STAT3 regulated the expression of ROR-t, a Th17-specific transcriptional regulator; STAT3 deficiency markedly decreased the expression of RORgt and RORa, which are now known to be lineage-specific transcription factors of Th17 cells [137] . Thus, STAT3 might up-regulate the expression of IL-17 by increasing the expression of RORgt and RORa, which are upstream of IL-17 production [137, 139] . These results indicated that STAT3 induces transcription factors, which possibly play an essential role in the global regulation of Th17 cell geneexpression programs. STAT3 has also been reported to be a crucial component of IL-23-mediated regulation of Th17 cells [140] [141] [142] [143] [144] [145] . In Chen and his colleagues' [144] studies, T cells deficient in SOCS3 (a negative regulator of STAT3) were found to have increased STAT3 activity in response to IL-23. Moreover, IL-17 production was also increased in SOCS3-deficient cells in response to IL-23 stimulation. As STAT3 binds to the IL-17 gene promoter, these investigators proposed that STAT3 mediates IL-23-regulated expression of IL-17, which is negatively regulated by SOCS3. These results indicated that IL-23 signals through STAT3 in T cells. As IL-23 is not important for the initial differentiation of Th17 cells, STAT3 might function at the effector stage to mediate IL-23-induced Th17 cell proliferation and cytokine expression. Yang et al. [137] showed that overexpression of a hyperactive form of STAT3 in T cells potentiated Th17 cell differentiation and conversely, that Th17 cell differentiation, mediated by TGF-b and IL-23, was defective in STAT3-deficient T cells. In the Figure 6 . Emerging role of halofuginone in IL-17/ Th17-dependent inflammatory and immune responses and the contribution of the areca nut in the pathogenesis of OSF: excessive chewing of the betel nut can lead to oral mucosal injury, which develops into OSF if highly progressive. Recent evidence suggests that IL-17/Th17 immunity is also central to the process of fibrogenesis and links established profibrogenic molecules and pathways, including TGF-b and various inflammatory cytokines, as well as novel profibrogenic mediators, such as DR-3 and ICAM-1, to myofibroblast proliferation and collagen deposition, resulting in OSF. Halofuginone selectively prevents the differentiation of Th17 cells by influencing these molecules and pathways.
absence of STAT3, these authors observed defects, not only in IL-17 production but also in the expression of IL-17F, IL-22, and IL-23R. Subsequently, STAT3 was also reported to be important for IL-21 expression and for IL-21-mediated Th17 cell differentiation [145, 146] .
Halofuginone prevents activation of the NF-kB signaling pathway, thus down-regulating inflammation by reducing levels of cytokines, chemokines, and adhesion molecules. NF-kB is a family of transcription factors that play critical roles in the regulation of immunity and inflammation by stimulating the transcription of a wide range of cytokine-encoding genes, including those encoding TNF-a and IFN-g. This family is composed of 5 related transcription factors (p50, p52, p65, cRel, and RelB) that can form homo-and heterodimers [147] . NF-kB signaling, upon ligation of receptors, including the BAFF receptor and CD40, leads to the activation and stabilization of NF-kB-inducing kinase, resulting in IKK1 activation and downstream NF-kB2 phosphorylation and processing to p52, which then dimerizes with RelB to regulate target gene expression. RelB was demonstrated to be crucial for the generation of IL-17-producing gd T cells [148] , a cellular subset with the capacity to restrain T reg responses during EAE [149] . Furthermore, NF-kB-mediated transcriptional activation contributes to fibroblast activation [150] . Fibroblasts, subjected to the local inflammatory response upon stimulation with LPS, release inflammatory mediators via IKK2, IkBa, and p65 activation [151, 152] . Additionally, RelB has been demonstrated to down-regulate inflammatory cytokines and chemokines and the inflammatory response in general [153, 154] , thus inducing the activity of fibroblasts. It has been reported that NF-kB can induce the expression and secretion of various inflammatory cytokines, including IL-17 and IL-6, and adhesion molecules, such as DR-3 and ICAM-1, excessive amounts of which contribute to fibrosis [155, 156] . Therefore, inhibition of NF-kB activity is considered an underlying mechanism for anti-fibrosis therapies [157, 158] . In addition to its ability to regulate cytokine production, NF-kB exerts its effect on the acute-phase response of inflammation [159, 160] . This may be another reason that halofuginone is effective against fibrosis.
CONCLUSION
Halofuginone, originally intended for use as an anti-malarial drug, was eventually used against fibrosis in conditions such as scleroderma and cGvHD. This drug has received increasing interest recently, in light of its wide range of beneficial biologic activities against fibrosis, malaria, solid plasma cell cancers, and Th17-mediated inflammatory autoimmune diseases. Studies have shown that halofuginone can reverse existing fibrosis in various animal models, including older mdx mice and humans [32, 81, 161] . Halofuginone, which can achieve effective therapeutic plasma levels at a dosage that is well tolerated [162] , simultaneously targets important inflammatory mediators and profibrotic cytokines and will probably emerge as a successful way to treat the highly complex and difficult-to-manage fibrotic pathology [163] .
However, several open questions remain unanswered. For instance, halofuginone affects distinct signaling pathways in different cell and tissue types, and it may therefore be desirable to avoid systemic administration. If halofuginone were found to be successful with minimal unwanted side effects in a clinical trial addressing a cell-or tissue-specific fibrotic indication, then it might be considered as an anti-fibrotic therapy for other indications as well. Additionally, as Zhang et al. [164] explained, linear synthesis of halofuginone hydrobromide can be achieved now, but only its anti-coccidial activity has been evaluated and verified so far. Therefore, if halofuginone can be specifically designed for the inhibition or promotion of some signaling pathway that plays a vital role in alleviating or even reversing fibrosis on the basis of Zhang and colleagues' methods [164] , then fibrosis may not be such a challenging problem in the near future. In conclusion, the outlook for the use of halofuginone against numerous fibrotic diseases appears bright, but many questions remain that must absolutely be explored further. 
